The use of psychedelics to self-treat depression and anxiety has become a popular alternative treatment to antidepressants and other available options offered to people experiencing these issues. One reason for this is the growing but still limited scientific legitimacy of psychedelics as a safe and effective treatment in certain contexts. The results of recent clinical studies have supported the use of full doses of psychedelics such a psilocybin for treatment-resistant depression and end-of-life anxiety when used in combination with therapy. This approach has been called “psychedelic-assisted therapy.”

David Kryszajtys, Ph.D. Candidate at the Dalla Lana School of Public Health, University of Toronto, asked me to design a logo for his study project. He wanted it to be representative of the type of research he does. I accomplished this through a custom illustrated “mushroom” graphic which acts as an indictor to the full study title.